Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF - Get Free Report) shares reached a new 52-week high on Friday . The stock traded as high as $28.14 and last traded at $28.14, with a volume of 100 shares. The stock had previously closed at $26.64.
Analyst Upgrades and Downgrades
Separately, Royal Bank of Canada upgraded shares of Hikma Pharmaceuticals from a "hold" rating to a "moderate buy" rating in a report on Tuesday, December 10th.
Read Our Latest Report on HKMPF
Hikma Pharmaceuticals Price Performance
The company's fifty day moving average price is $25.16 and its 200 day moving average price is $25.08. The company has a quick ratio of 0.98, a current ratio of 1.66 and a debt-to-equity ratio of 0.46.
Hikma Pharmaceuticals Company Profile
(
Get Free Report)
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Read More
Before you consider Hikma Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hikma Pharmaceuticals wasn't on the list.
While Hikma Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
